• 1. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Introduction to 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole (CAS No. 886904-89-8) and Its Emerging Applications in Chemical Biology

1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole, identified by the CAS number 886904-89-8, is a structurally complex organic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, featuring a benzodiazole core substituted with a 2-methylphenylmethyl group and a propane-1-sulfonyl moiety, exhibits unique chemical properties that make it a promising candidate for various biological assays and drug discovery initiatives.

The benzodiazole scaffold is well-documented for its pharmacological relevance, particularly in the modulation of central nervous system (CNS) activities. However, modifications to the benzodiazole structure can lead to compounds with altered pharmacokinetic profiles and novel biological activities. The presence of the 2-methylphenylmethyl group in 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole introduces steric and electronic influences that can fine-tune its interactions with biological targets. This substitution pattern has been explored in recent studies as a means to enhance binding affinity and selectivity toward specific enzymes and receptors.

Moreover, the propane-1-sulfonyl group at the 2-position of the benzodiazole ring introduces a sulfonate moiety, which is known for its ability to improve water solubility and metabolic stability. Such structural features are increasingly sought after in drug design, as they can enhance bioavailability and reduce systemic toxicity. The combination of these modifications makes 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole a versatile compound for investigating mechanisms of action in neurological disorders, such as anxiety and epilepsy.

Recent advancements in computational chemistry have enabled the rapid screening of analogs like 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole for potential therapeutic applications. Molecular docking studies have suggested that this compound may interact with neurotransmitter receptors, such as GABA-A receptors, which are implicated in anxiety-related disorders. The sulfonate group’s ability to form hydrogen bonds with polar residues in the receptor binding pocket could enhance its binding affinity. Additionally, the 2-methylphenylmethyl group may contribute to favorable hydrophobic interactions, further stabilizing the compound-receptor complex.

In vitro studies have begun to explore the pharmacological profile of 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole, revealing promising results in modulating CNS activity. Preliminary data indicate that this compound exhibits anxiolytic-like effects without producing significant sedation at therapeutic doses. This is an encouraging finding, given that many benzodiazepine analogs suffer from issues related to tolerance and dependence. The unique structural features of 886904-89-8 may contribute to its favorable pharmacological profile by reducing off-target effects associated with traditional benzodiazepines.

The synthesis of 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Key synthetic steps include Suzuki-Miyaura cross-coupling reactions for constructing the benzodiazole core, followed by sulfonylation reactions to introduce the propane-1-sulfonyl group. Advances in flow chemistry have recently enabled more efficient synthesis routes for complex molecules like this one, reducing reaction times and improving scalability.

From a regulatory perspective, compounds like 886904-89-8 must undergo rigorous safety evaluations before they can be considered for clinical use. Toxicology studies are essential to assess potential hepatotoxicity, nephrotoxicity, or other adverse effects associated with long-term exposure. Collaborative efforts between synthetic chemists and biologists are crucial for designing experiments that provide comprehensive data on safety and efficacy. The growing interest in CNS-targeting compounds has spurred innovation in preclinical testing methodologies, ensuring that promising candidates like this one are thoroughly characterized before advancing to human trials.

The future prospects for 1-(2-methylphenyl)methyl-2-(propane-1-sulfonyl)-1H-1,3-benzodiazole extend beyond its potential as an anxiolytic agent. Researchers are exploring its utility as a tool compound for studying neurotransmitter signaling pathways and developing novel therapeutic strategies for neurodegenerative diseases. The sulfonate group’s ability to modulate protein-protein interactions makes it an attractive candidate for designing molecules that can interfere with pathological processes associated with conditions such as Alzheimer’s disease or Parkinson’s disease.

In conclusion, 886904-89-8 represents a significant advancement in the development of CNS-active compounds due to its unique structural features and promising pharmacological properties. Its synthesis challenges highlight the intersection of organic chemistry innovation with computational biology tools, paving the way for more efficient drug discovery pipelines. As research continues into its biological activity, 886904 -89 -8 holds promise not only as a potential therapeutic agent but also as a valuable tool for understanding fundamental aspects of neural function.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)